NSE · AJANTPHARM · Pharmaceuticals
Ajanta Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,489 Cr with net profit ₹315 Cr — a 21.19% net margin, versus 18.77% the period before.
Shareholding
As of 2026-06-30
- Promoter63.48%
- Public7.03%
- FII7.68%
- DII21.8%
65,296 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.63× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 2.76 percentage points to 63.48% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #3 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,87,712 Cr | 84.13 | 22.57 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,127 Cr | 42 | 4.65 | 9.92% | 16.78% |
| Ajanta Pharma Limited(this company) | ₹43,977 Cr | 38.75 | 9.72 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹27,664 Cr | 95.99 | 21.47 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹21,111 Cr | 31.73 | 6.27 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹20,207 Cr | 71.06 | 7.8 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹17,617 Cr | 26.82 | 4.52 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹15,088 Cr | 29.21 | 4.99 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,386 Cr | 53.64 | 6.15 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,355 Cr | 50.29 | 6.81 | 12.36% | 18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashAjanta Pharma Limited is listed on the Indian markets with a market capitalization of Rs 43340 Cr. The company reported a revenue of Rs 4742.6 Cr with a revenue growth of 10.4% and a profit margin of 19.37%. Its PE ratio is 162.48 and EPS is 90.33. The book value per share stands at Rs 362.35. Return on equity is 23.33% and return on capital employed is 29.09%. The debt-to-equity ratio is 0.04.
Positives
- +The debt-to-equity ratio is low at 0.04, indicating limited reliance on debt.
- +The company demonstrated a revenue growth of 10.4%.
- +Return on Capital Employed (ROCE) is 29.09%, indicating efficient use of capital.
- +The profit margin is 19.37%.
Negatives
- −The promoter pledged 22.53% of their shareholding.
- −Promoter pledge increased from 11.16% in July 2017 to 22.53% in June 2026.
- −The trailing PE ratio of 162.48 is significantly higher compared to its EPS of Rs 90.33.
Financial performance
Ajanta Pharma Limited recorded a revenue of Rs 4742.6 Cr, indicating a revenue growth of 10.4%. The company's profit margin for the period was 19.37%. Annual net profit for Mar 2026 was Rs 1056 Cr on revenue of Rs 5624.93 Cr. Quarterly revenue for March 2026 was Rs 1421.64 Cr, with a net profit of Rs 266.7 Cr.
Profitability & Returns
The company's profit margin is 19.37%. Return on equity (ROE) is 23.33%, and return on capital employed (ROCE) is 29.09%. The earnings per share (EPS) is Rs 90.33. The latest annual EPS reported for Mar 2026 was Rs 84.51.
Balance Sheet
Ajanta Pharma Limited maintains a low debt-to-equity ratio of 0.04, suggesting a limited reliance on debt financing. The book value per share is Rs 362.35. The company’s 52-week high was Rs 3506.9 and its 52-week low was Rs 2329.9.
Ownership & Pledges
Institutional holdings include 21.80% by DIIs and 7.68% by FIIs. The public holds 7.03% of the shares. Total institutional holding stands at 29.48%. Promoter pledged shares account for 22.53% of the promoter holdings.
Data as of — price: 2026-09-23 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.